Intra-arterial injection of iodine-131-labeled lipiodol for treatment of hepatocellular carcinoma.
OBJECTIVE
The therapeutic effect of intra-arterial injection of 131-iodine-labeled lipiodol for treatment of hepatocellular carcinoma in palliative or adjuvant settings has been promising. We report, the results of an open study of this therapy in cirrhotic patients with small hepatocellular carcinoma.


METHODS
Forty patients with hepatocellular carcinoma were given intra-arterial injections of 131-iodine-labeled lipiodol. These injections were repeated if necessary every 3 months. Tumor response (WHO criteria) was determined on CT scans performed after each treatment and every 3 months during the follow-up. Side effects and the cause of death were recorded. Therapeutic response and survival were analyzed.


RESULTS
The median number of treatment was 2 (1-4). There was one complete response, 18 partial responses (47.5% response rate); 19 had stable disease and 2 progressions. Overall survival rates (+/-CI 95%) at 1, 2 and 3 years were: 90+/-4.7%, 60.3+/-8%, and 39+/-8.3%, respectively. Median survival was 27 months; 25 patients have died (4-56 months), 8 of tumor progression with a multifocal spread in the liver. Tolerance was good except for 2 patients who develop a fatal drug-related pulmonary insufficiency.


CONCLUSIONS
These data suggest that intra-arterial therapeutic injection of 131-iodine-labeled lipiodol for treatment of hepatocellular carcinoma can provide high rate response and long survival for individuals not eligible for surgery or local treatment.
Boucher
Eveline
E
Department of Medical Oncology, Centre Eugène Marquis, Rennes, France. boucher@rennes.fnclcc.fr
Garin
Etienne
E
Guylligomarc'h
Anne
A
Olivié
Damien
D
Boudjema
Karim
K
Raoul
Jean-Luc
JL
D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000532:radiotherapy*; D003287:Contrast Media / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007269:Injections, Intra-Arterial; D007457:Iodine Radioisotopes / Q000008:administration & dosage; D007459:Iodized Oil / Q000008:administration & dosage / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000401:mortality / Q000532:radiotherapy*; D008297:Male; D009367:Neoplasm Staging; D016019:Survival Analysis; D016896:Treatment Outcome
D003287:Contrast Media; D007457:Iodine Radioisotopes; D007459:Iodized Oil